# Cytogenetics & molecular cytogenetics

Mgr. Marketa Wayhelova, PhD Mgr. Marta Navarikova



Faculty of Medicine, Masaryk University University Hospital Brno



# WARNING

- This presentation is intended exclusively for educational purposes
- Every form of misuse, including copying, distribution and sharing on public online platforms or social media (YouTube, Facebook etc.) is strictly prohibited and can be punished

# WHAT ARE WE GOING TO TALK ABOUT?

- 1. Department of Medical Genetics, genetic laboratories
- 2. What is cytogenetics
- 3. History
- 4. Chromosome morphology and aberrations
- 5. Molecular cytogenetics and its techniques
- 6. Case interpretation
- 7. Our laboratory and work

## DEPARTMENT OF MEDICAL GENETICS

- Medical specialists providing highly specialized and complex genetic counselling for different types of patients and diagnoses
  - infertility, recurrent abortions
  - preimplantation and prenatal diagnostics (abnormal screening)
  - developmental delay, intellectual disability, congenital somatic abnormalities, monogenic disorders.. (solitary or familial)
  - Familial segregation of various types of disorders (chromosomal abnormalities, monogenic disorders, etc.)
  - Familial occurrence of cancers
  - Oocyte and sperm donors

. . . . . .

#### Clinical diagnoses must by confirmed on the molecular level (chromosomes, DNA)!



# 1. WHAT IS CYTOGENETICS?

 Cytogenetics is a branch of genetics focusing on the study of chromosome changes (number, morphology, numerical and structural abnormalities, segregation in normal and pathological conditions) and their correlation with phenotype.

## 2. A BRIEF HISTORY OF (CYTO)GENETICS

- 1866 Gregor Johan Mendel Experiment in Plant Hybridization
- Father of genetics
- Defined the basic principals of heredity (principle of segregation and combination)
- During his life, his work was ignored
- Later, Mendel s work was rediscovered
- 1910 Thomas Hunt Morgan proved that genes are located on chromosomes (using Drosophila)
- 1953 James Watson and Francis Crick determined DNA structure
- 1956 Tjio, Levan Human chromosome number is 46

## HISTORY OF HUMAN CYTOGENETICS

- **"Dark Ages"** the development and improvement of tissue culture techniques
- "Hypotonic Period"
  - hypotonization of cell samples (1951 0,075 m KCl)
  - utility of phytohaemagglutinin (PHA) stimulation of peripheral blood lymphocytes - 1960
- "Trisomy Period" trisomy of chromosome 21-1959
- The first deletion syndrome "Cri du chat" 1963
- "Banding Area" chromosome banding techniques 1968 1970
- "Molecular Area"
  - in situ hybridization technique 1970
  - FISH 1986
  - Comparative genomic hybridization (CGH) 1992
  - spectral karyotyping (SKY), multicolor FISH (M-FISH) 1996
  - m-banding 2001
  - array-CGH (molecular karyotyping)

#### NOMENCLATURE OF HUMAN CHROMOSOMES

> **1960:** Denver Conference - sort of human chromosomes into groups according to size and shape

- 1963: London Conference chromosomes are sorted into 7 groups A – G
- > 1966: Chicago *Conference* the description of chromosome changes
- > **1971:** *Paris Conference* - the identification and labeling of chromosomes using banding techniques
- An International System for Human Cytogenetic Nomenclature

(ISCN 1978; ISCN 2016 in present)



Editors Lisa G. Shaffer

## 3. CHROMOSOME MORPHOLOGY



#### CHROMOSOME MORPHOLOGY



\*note: telocentric chromosomes are not present in human karyotype

## CHROMOSOME STAINING

- Classical painting
  - using Giemsa Romanowski solution
  - Detection of acquired chromosome aberations
- G bands
  - using trypsin, salty solution and Giemsa
  - each chromosome has characteristic pattern (dark bands – A/T rich, light bands – G/C rich)
  - Detection of congenital chromosomes aberations (mostly > 10 Mb)
- R bands
  - using salty solution of different pH and temperature
  - reverse to G bands





#### METHODOLOGY FOR CLASSICAL AND BANDING CYTOGENETICS

- To drop processed cell suspension with mitoses on microscopic slides
- Staining to obtain chromosomal bands
  - 1) digestion the specimen in trypsin solution
  - 2) staining in Giemsa-Romanovski dye
- Evaluation in light microscope with CCD camera
- -> to get karyotype (computational analysis of image)









NORMAL MALE KARYOTYPE (46,XY)



## HUMAN KARYOTYPE – 7 GROUPS OF CHROMOSOMES



## HUMAN SOMATIC CELL CONTAINS:

#### 23 pairs or 46 chromosomes

- 22 pairs of autosomes (1-22)
- 1 pair of gonosomes (XX or XY)
- 7 groups ordered according to chromosome size and morphology
  - A large metacentric chromosomes
  - B large submetacentric chromosomes
  - C middle-sized submetacentric chromosomes and chromosome X
  - D large acrocentric chromosomes
  - E small meta- to submetacentric chromosomes
  - F the smallest metacentric chromosomes ("ribbons")
  - G small acrocentric chromosomes and chromosome Y

		KAI	RYOTI	(PES (	OF ANI	MALS			(EXAM	PLES)		
	2	3		<b>)</b> () 5	A 0	69	98	Ĥ		R R		100 100
A A	8	8 9	19	11	12		2 1 1 9	3 	6 8 8	5	6 0 0 13	7 6 A 14
13	<b>1</b> 4	15	16	17	18	15	16	ð	6 67	19	A A 28	21
19	0 0 28	<b>A A</b> 21	6 A 22	<b>Å</b> Å 23	1 A 24	<b>A G</b> 22	Λ Â 23	<b>8</b> 8 24	10 A 25	4 5 A 26 27	<b>A</b> A 28	<b>A A</b> 29
۵ ۸ 25	ê â 26	ñ û	<b>\$ \$</b>	<b>6 6</b>	Å Å	6.6		0 61		6 6 2	64 46	~ *
Cattle	e (2n=6	0)	8	X X 1	8 8 8	<u>م</u> م 4	X X 5		31	<u> </u>	Dog (2n	=78)
			*		8 K K K	<b>8 8</b> 9	<b>X X</b> 10	X X				
			۵	<b>N N I</b> 14 15		<u>ត</u> ិ <b>ព</b>	<b>1</b> 8	0 0 19				
			0		A 9 Å 22	23 ~ ^ ^	24 30	ΛΛ 25	Horse (2	2n=64)		

# CHROMOSOME ABERRATIONS

## AUTOSOMES

- 1. Structural chromosomal aberrations
  - Polymorphisms
    - different lenght of chromosomes in homologous pair
    - <u>no phenotype effect</u>

## Inversion

- pericenric including centromere
- paracentric does not include centromere
- usually has no phenotype effect in its carrier

#### Ring chromosomes

breaks on both chromatides and their connection

ghr.nlm.nih.gov/handbook/illustrations/ringchromo

- loss of telomeric parts
- intellectual and physical impairment
- always newly created



18

# CHROMOSOME ABERRATIONS

- **Deletion** = loss of part of chromosome ->unbalanced karyotype
  - terminal one break and loss of a terminal part
  - interstitial two breaks and loss of a part between centromere and terminal part
  - <u>deletion syndromes</u> examples:
    - Wolf-Hirschhorn syndrome (4p deletion), Cri-Du-Chat syndrome (5p deletion)
  - <u>microdeletion syndromes</u> examples:
    - Prader-Willi syndrome; 15q11-q13 deletion
    - DiGeorge syndrome; 22q11.2 deletion
    - Angelman syndrome; 15q11-q13 deletion
    - Williams-Beuren syndrome; 7q11.23 deletion
- **Duplication** = gain of chromosomal part -> unbalanced karyotype
  - Typically less harmful than deletions
- Insertion
  - inserted part can be in the same or inverted position



#### Translocation

- <u>reciprocal</u>
  - mutual exchange between two or more nonhomologic chromosomes
  - balanced no phenotype effect for carriers
  - genetic risk of unbalanced genomes in carrier's offspring
- <u>Robertsonian</u>
  - between two acrocentric chromosomes
  - breaks in the area of centromeres and deletion of short arms
  - centric fusion of the remaining arms
  - balanced normal phenotype
  - genetic risk for offspring
- <u>Simple</u>
  - One break in the arm of one chromosome
  - Fusion of the broken part with another chromosome



http://www.larasig.com/node/3628



http://drugline.org/medic/term/robertsonian-translocation/

#### Marker chromosomes

- Small supernumerical chromosomes (with centromere)
- Often in mosaic form
- Sometimes difficult to identify the origin

#### Isochromosomes

Metacentric chromosomes – one arm is lost, the second one is duplicated

#### Dicentric chromosomes

- Breaks on two chromosomes
- Fusion of parts with centromeres
- Acentric fragment is lost







## CHROMOSOMAL ABERRATIONS - OVERVIEW



M Moore, Charleen & Best, Robert. (2001). Chromosomal Genetic Disease: Structural Aberrations. 10.1038/npg.els.0001452.

## CHROMOSOME ABERRATIONS

• 2. Numerical

# Trisomy

- 21 chromosome trisomy Down syndrome
- 18 chromosome trisomy Edwards syndrome
- 13 chromosome trisomy Patau syndrome

# Triploidy

- 69 XXX, 69 XXY
- nonviable
- <u>mosaic</u> triploidy mental retardation, syndactyly, abnormal genitals, lateral asymetry

#### CHROMOSOME ABERRATIONS

#### GONOSOMES

#### • Chromosome Y

- structural aberrations very rare
- numerical aberrations
  - 47, XYY supermale syndrom

#### Chromosome X (males)

- Numerical aberration
  - 47, XXY Klinefelter syndrom

#### Chromosome X (females)

- numerical aberrations
  - 45, X Turner syndrom
  - 47, XXX XXX syndrom

#### Fragile X – FRA-X

- the most common cause of intellectual disability (excluding trisomy 21)
- nonspecific phenotype (intellectual impairment, facial dysmorphology, ...)

#### CHROMOSOMAL MOSAICISM

- Chromosomal aberrations are mostly in all human cells
- Mosaicism = 2 or more cell lines with different karyotype in human body
- Nondisjunction in early post-zygotic mitotic division (prenatal period)
- Numerical more frequent than structural
- Most often in gonosomal aneuploidies (-> spontaneous abortions, infertility)
  - Example: 45,X[6]/47,XXX[4]/46,XX[190]
- Autosomal aneuploidies
  - Example: mosaic form of Down syndrome

47,XY,+21[172]/46,XY[28]

## DOWN SYNDROME (47,XX OR XY,+21)

- 1866 J.L.Down
- IQ 25-50
- short stature
- round face
- short neck
- mongoloid eyes
- epicanthus
- wide nose root and flattened nose
- small mouth, large tongue, small teeth
- single transverse palmar crease
- heart diseases









## EDWARDS SYNDROME (47, XX OR XY,+18)

- growth retardation
- microcephaly
- dolichocephaly elongated head
- cleft palate
- low-set malformed ears
- specific finger holding
- structural heart defect at birth
- survive only few months

	ALCONOMIC 2	can observationally 3			Accession of the operation of the operat	Alterstatistics
Ņ	Annes and	distance 8	South State	200612010 <sup>10</sup> 200-002000 10	340-03403 1	and the second s
<sup>7</sup> bellagers		Section 2		1000	্রাজনার ব্যক্তিয়া	dige6 Buseo
13 3	14 92/0	15		16 ਵੇਵੇਂ	17 5000	18
19 © Clinical Too	20			21	22 X	Y

Karvotype from a female with Edwards syndrome (47.XX.+18)





#### PATAU SYNDROME (47,XX OR XY,+13)

- severe somatic retardation and neurodevelopmental disorders
- microcephaly
- trigonocephaly
- cutis aplasia
- congenital brain defects
- cleft palate
- hexadactyly
- kidney defects







### PRADER-WILLI SYNDROME (DEL 15Q11-Q13)

- deletion of paternal locus 15q11-q13
- low fetal activity
- hypotonia
- excessive weight gain, hyperphagia
- short stature
- hypogonadism
- intellectual disability
- hypopigmentation
- skeletal development delay (acromicria)





## ANGELMAN SYNDROME (DEL 15Q11-Q13)

- deletion of <u>maternal locus15q11-q13</u>
- severe intellectual impairment
- hypotonia
- epilepsy, seizures
- hypopigmentation
- hyperactivity
- speech absence
- prominent scull shape (mandibular shape, microcephaly, flat back of head..)
- "happy puppet" syndrome
- movement/balance disorder



## DIGEORGE SYNDROME (DEL 22Q11.2)

- low-set malformed ears
- small mouth and lower jaw
- narrow eyelids
- submucosal or visible cleft palate
- hypocalcemia
- interrupted aortic arch
- cardiac abnormality tetralogy of Fallot
  - incomplete ventricular septum
  - right-to-left shunt of aorta
  - left ventricle hypertrophy
  - lung stenosis





https://www.google.cz/search?q=digeorge+syndrom&&espv=210&es\_m=93&source=Inms&tbm=isch&sa=X &ei=P9CFUo21HsqR7AbP1IBI&ved=0CAKQ\_AUAAQ&biw=1920&bih=969#facrc=\_&imgdii=\_&imgrc=0EhFF G2IOAvB3M%3A%3BFG4R33YXEx/hsM%3Bhttp%253A%252F%252Fd



#### WILLIAMS-BEUREN SYNDROME (DEL 7Q11.23)

- developmental delay
- mental disability
- failure to thrive
- heart defects (heart murmur, narrowing of main blood vessels)
- flattened nasal bridge
- widely spaced teeth
- hypercalcemia
- gastrointestinal problems
- urinary difficulties



https://www.google.cz/searth?q=williams+beuren+syndrome&source=Inms&thm=isc https://www.google.cz/searth?q=williams+Geder0CAcQ\_AUoAQ&biw=1920&bih=98 9#facre\_&imgdile\_&imgrc=MdTDkcoWBwg-WIM%3A%3BTKV2TKD/mYM%3Bhttp%253A%252F%252Fwww.thespeciallife.com %262Fimages%252F



https://www.google.cz/search?q=williams+beuren+syndrome&source=Inms&tbm =isch&sa=X&ei=MimGUVbpC4CctQaIhYGwCg&ved=0CAcQ\_AUoAQ&biw=192 0&bih=999#facrc\_\_&imgdi=\_kimgc=HTIyFEuSnZo4JM%3A%3BkqK81uaGRtK PIM%3Bhttp%253A%252F%252Fgenetics1.iaba

## KLINEFELTER SYNDROME (47,XXY)

- tall stature
- less facial and body hair
- female distribution of body fat
- hypogonadism (decreased testicular hormon function)
- infertility
- gynecomastia (increased breast tissue)
- mild intellectual impairment
- variations: 48, XXYY; 48, XXXY; 49,XXXXY





## TURNER SYNDROME (45,X)

- lower birth length and weight
- low hairline
- pterigyum
- broad chest, widely spaced nipples
- small growth
- infertility, amenorrhea
- coarctation of the aorta
- webbed neck
- lymphedema







# THE LINK BETWEEN KARYOTYPING (K) AND MOLECULAR CYTOGENETICS (MC)

- Using MC methods to confirm and specify pathological chromosomal aberrations detected by G-banding K
  - Aneuploidies -> FISH
  - Structural chromosomal rearrangements -> FISH, array-CGH
- MC methods can detect very subtle chromosomal rearrangements, which escaped detection using G-banding K (due to its low resolution > 5-10 Mb)

# 4. MOLECULAR CYTOGENETICS

- Interconnection and combination of approaches of classical cytogenetics and molecular biology
- Utility of the latest knowledge of molecular biology, microscopy and computer image analysis to study the structure and properties of chromosomal changes
- Ability to analyse both numerical and structural chromosomal imbalances unidentified classical cytogenetic techniques
- does not require the presence of mitosis for most applications
- sources of material for cytogenetic investigation
  - peripheral blood
  - samples from different tissues
  - amniotic fluid cells, chorionic villi, placenta umbilical cord blood
  - bone marrow
  - samples of solid tumors





solid tumor
# MOLECULAR CYTOGENETICS

The key interest of the laboratory of molecular cytogenetics is the identification and analysis of chromosomal aberrations using molecular cytogenetic approaches



### FISH FLUORESCENT IN SITU HYBRIDIZATION



FISH

- detection of the fluorescent signals through microscope equipped with specific fluorescent filters
- material
  - cultivated peripheral blood
  - cultivated bone marrow
  - cultivated amniotic fluid cells
  - uncultivated amniocytes
  - tumor and bone marrow prints
- we determine:
  - 1. presence of signals
  - 2. number of signals
  - 3. position of signals
- the use of FISH
  - clinical cytogenetics
  - oncocytogenetics
  - human genome mapping







# METHODS

Fluorescence in situ hybridization (FISH)



 Comparative genomic hybridization (CGH) or High resolution-CGH (in past)

array-CGH

MLPA





t(11;14)







# THE EQUIPMENT

### **Classical Cytogenetics, FISH, CGH/HR-CGH**

- Microscopes Olympus BX61
- CCD cameras Voskuhler
- Digital Image Analysis System (LUCIA, LIM Lt)
  - LUCIA-KARYO
  - LUCIA-FISH
  - LUCIA-CGH/CGH Advanced Statistics

System for SKY (SKY View – Applied Spectral Imaging Ltd., Israe

**System for array-CGH**: SureScan Microarray Scanner (Agilent Tech.)

System for MLPA: capillary electrophoresis (Beckman Coulter)











MOLECULAR CYTOGENETIC INVESTIGATIONS (LABORATORIES OF CYTOGENOMICS)

APPLICATIONS OF FISH

- Prenatal cytogenetic diagnosis
- Postnatal cytogenetic analyses
- Cancer cytogenetic analyses

### PRENATAL CYTOGENETIC ANALYSES

- Uncultered and cultured amniotic cells, fetal blood cells, chorionic villi cells
- interphase FISH (I-FISH) for aneuploidies
- metaphase FISH (in specific cases)

#### FAST FISH Prenatal Enumeration Probe Kit (Cytocell)

Mix1:

- CEP 18 Sp. Aqua
- CEP X Sp. Green
- CEP Y Sp. Orange *Mix 2:*
- LSI 21 Sp. Orange
- LSI 13 Sp. Green

### Microdeletion syndromes (DiGeorge, Prader-Willi, Angelman, Williams-Beuren, ...)





### Prenatal cytogenetic analyses

#### Example: FISH on uncultured and cultured cells/mitoses



POSTNATAL CYTOGENETIC ANALYSES

- material: peripheral lymphocytes, buccal swab
- methods: FISH, array-CGH, MLPA



ToTel Vysion Kit, Abbott-Vysis

- Microdeletion syndromes FISH probes, MLPA kits P245, P297 (targeted detection)
  - DiGeorge syndrome
  - Prader-Willi/Angelman syndrome
  - Williams-Beuren syndrome
  - 1p36 microdeletion syndrome, etc.
- Subtelomeric screening MLPA kits P036, P070 (MRC-Holland), FISH ToTel Vysion kit (Vysis)
- Origin of marker chromosomes array-CGH, WCP FISH probes
- Identification and specification of numerical and structural aberrations
  array-CGH (in specific cases SKY)
- Detection of gonosomal mosaicism FISH (X/Y probes) in infertile couples or gonosomal syndromes

# Postnatal cytogenetic analyses

 $X \rightarrow Y$ 

FISH: 46,XX/46,XY (mosaicism)





FISH: deletion of (22)(q11.2) (DiGeorge syndrome) SKY: identification of marker chromosome (chr. 11)

# CANCER CYTOGENETIC ANALYSES - SOLID TUMOURS

# Cultivated and uncultivated solid tumors (tumour prints)

• FISH, M-FISH/SKY, CGH

### Children solid tumours

### •FISH: targeted analysis (panel testing)

- **Neuroblastoma** –MYCN amplification, 1p36 deletion, gain 17q, 11q deletion;
- **Medulloblastoma** MYCN, MYCC amplification

 array-CGH: whole genome screening of unbalanced chromosomal aberrations (and losses of heterozygosity)



Tumor

Neuroblastoma

### ADVANTAGES AND DISADVANAGES OF FISH

- advantages
  - does not require the presence of mitoses (for most applications)
  - quick assessment of big amount of cells
- disadvantages
  - does not provide whole genomic view
  - can detect only a <u>specified</u> locus or a limited number of loci (using fluorescent-labeled DNA probes)

### **SKY** SPECTRAL KARYOTYPING

- Microscope equipped with 2 fluorescent filters (SKY, DAPI)
- fluorochromes (FITC Rhodamin TexasRed Cy5 Cy5.5) scanned by one filter, based on a wave lenght each chromosome pair is coloured → pseudocolours



Image Acquisition with SkyVision<sup>™</sup>

### Image analysis using SkyView



**Display Image** 

Classified Image

The SkyView spectral karyotyping software is able to automatically classify and karyotype chromosomes in the Display image, thereby overcoming the ambiguity inherent in the display colors.



# ADVANTAGES AND DISADVANTAGES OF SKY

#### • advantages

- detects balanced rearrangements
- detects aberations in one step
  - cryptic translocations and insertions
  - marker chromosomes
  - redundant material with unknown origin
  - complex rearrangements
- <u>disadvantages</u>
  - need of quality mitoses
  - succesful hybridisation
  - expensive method

### CGH - COMPARATIVE GENOMIC HYBRIDIZATION HR-CGH - HIGH-RESOLUTION CGH ARRAY-CGH

- improvement of FISH technique to measure DNA gains or losses throughout the entire genome
- detection of unbalanced chromosomal changes (gains or losses) throughout an entire genome in one hybridization reaction
- is based on **<u>comparison</u>** of two genomes

#### FISH

normal DNA  $\rightarrow$  select DNA  $\rightarrow$  make probe (limited number of targets in one hybridization)  $\rightarrow$  label abnormal target  $\rightarrow$  abnormal target identified

#### CGH/HR-CGH/array-CGH

normal DNA  $\rightarrow$  no DNA selection  $\rightarrow$  **make probe (entire genome)**  $\rightarrow$  quantify on normal target  $\rightarrow$  abnormal genome quantified

### **Requirements**

- Good quality DNA isolated from
  - peripheral blood
  - bone marrow
  - solid tumour
  - amniocytes, CVS, ...









### Equipment:

- •Fluorescent microscope (filters DAPI, Spectrum Green, Spectrum Red)
- Sensitive CCD kamera
- Computer with software for CGH analysis and data interpretation, (LIM, Czech Republic)
  CGH/HP-CGH
- CGH/HR-CGH
- •Hybridization oven, microarray scanner
- •Computer with software for array-CGH analysis and data interpretation array-CGH

# **CGH principle**



www.abbottmoleculars.com

# **CGH principle**





www.abbottmoleculars.com



Relative brightness depends on amount of labeled DNA with appropriate complementary sequences, i.e. on the DNA copy number at this locus

# Mitoses scanning, CCD camera filters for B, G, R



### **Identification of aberrations**

Florescent ratio profile is compared to the fixed tresholds (15-20% from ratio 1). The ratio profile that deviates 15 % - 20 % from ratio 1.0 is typically regarded as aberrant.





# ADVANTAGES OF CGH

- detects and quantifies DNA copy number gains and losses throughout an entire genome in a single analysis
- does not require cell culturing and metaphases from test tissue
- is able to identify not only the chromosome from which the additional unknown material is derived, but also to map the region involved to specific bands on the source chromosome
- in combination with whole-genome PCR, can analyze DNA from a single or very few cells

# DISADVANTAGES OF CGH

- low sensitivity: about 10 Mb for single copy changes
  - solution: array-CGH
- does not detect balanced rearrangements (inversions, balanced translocations)
  - solution: mFISH
- cannot detect overall ploidy changes, e.g. tetraploid tumor
  - solution: use in conjunction with regular FISH
- requires minimally 50 % aberrant cells for reliable results
  - solution: HR-CGH, array-CGH

# **MODIFICATIONS OF CGH**

## High Resolution Comparative Genomic hybridization (HR-CGH)

- Kirchhoff *et al.,* 1997
- the same principles and laboratory processing as CGH
- different data interpretation based on <u>dynamic standard reference intervals</u> special analytical software
- genome resolution is about 4 Mb
- abnormal cell detection limit is about 30 %



### **Array-based comparative genomic hybridization (array-CGH)**

- Solinas-Toldo et al. 1997
- based on principle of CGH
- current routine approach of whole-genome screening of unbalanced chromosomal aberrations (including those of submicroscopic size < 5-10 Mb)
- nowadays fully replaces classical CGH and HR-CGH analysis
- the chromosomes on slide (CGH) are replaced by separated clones (array-CGH) (BAC – bacterial artificial chromosome, PAC – phage artificial chromosome, nowadays in most designs – oligonucleotides (miniaturized array)

CGH



### The origin of clones

BAC, PAC, c-DNA clones (in past), oligonucleotides



### GENERAL PRINCIPLE OF ARRAY-CGH

- Effective approach of the whole-genome screening of unbalanced chromosomal rearrangements in one hybridization reaction
- Co-hybridization of differently labeled DNA samples (patient's DNA and reference DNA) on DNA microarray covered by a large amount of oligonucleotide fragments (representing whole genome)
- Losses and gains of genetic material in patient's DNA are assessed from spots with abnormal ratios of signal intensities

Who are the most suitable patients?

- Individuals with neurodevelopmental disorders (intellectual disability, autism spectrum disorders), multiple congenital abnormalities, facial dysmorphology, ...
- Prenatal samples abnormal pregnancy (prenatal screening)
- Fetal tissue (abortions)
- Tumor tissues (solid tumors, bone marrow, ...)



# Array CGH: The Complete Process

- Steps 1-3 Patient and control DNA are labeled with fluorescent dyes and applied to the microarray.
- Step 4 Patient and control DNA compete to attach, or hybridize, to the microarray.
- Step 5 The microarray scanner measures the fluorescent signals.
- Step 6 Computer software analyzes the data and generates a plot.



# **Brief schema of sample processing using array-CGH**















Types of DNA microarrays (Agilent Technologies)

- ✓ 1X1M
- ✓ 2X400K
- ✓ 4X180K
- ✓ 8X60K

(parametres on www.agilent.com)

#### Agilent Feature Extraction for Cytogenomics – microarray scan 4X180K CGH+SNP



### Agilent Feature Extraction for Cytogenomics – microarray scan 8X60K CGH

👫 Agilent Feature Extraction for CytoGenomics - [D:\ScanData\Marketa\2019\2019-04-02\252192446021_S01 Red/Green]	
<u>F</u> ile <u>V</u> iew <u>E</u> dit C <u>o</u> lor <u>I</u> ools Feature E <u>x</u> traction <u>W</u> indow <u>H</u> elp	_ & ×
🔢 🗈 All Channels 👻 🕂 🍭 🔍 🔍 💺 Auto Color Scaling 🕶 🛃 1 🛛 📜	
	Grid Template Browser # ×
	014693_20111015
	014950_20101001
	016774_20091124
	021529_20111015
	021850_20150623 =
	- 021924_20090227
	-021924_20101001
	028081_20100921
	029830_20100916
网络马斯特斯马特 网络马斯特斯特特 网络马斯特特特特特 网络马斯特特特特特	029830_20100921
	- 029830_20111015 - 030587_20111015
	FE Protocol Browser + ×
Material and a second	CGH_1100_Jul11
	CytoCGH_0209_1x_Mar14
	CytoCGH_0209_2x_Mar14
	CytoCGH_0209_4x_Mar14
	CytoCGH_0209_8x_Mar14
	QC Metric Set Browser 4 ×
	CGH_QCMT_Jul11
	CytoCGH_QCMT_1x_Mar14
	CytoCGH_QCMT_2x_Mar14
	CytoCGH_QCMT_4x_Mar14
	CytoCGH_QCMT_8x_Mar14
Zoom = 10% (col = 0, row = 0) Red = 9, Green = 59	NUM
	📮 🚱 🞼 🛆 🚨 🖶 🖾 🍰 🛷 🚖 🚸 🔗 🕪 🏲 🔛 16:58
	23.4.2019
#### QC Report - Agilent Technologies : 2 Color CGH

Date	Friday, March 22, 2019 - 14:51	Sample(red/green)
User Name	admin	FE Version
Image	252192446022_801 [1_1]	BG Method
Protocol	CytoCGH_0209_4x_Mar14 (Read Only)	Multiplicative Detrend
Grid	021924_20101001	Dye Norm
Saturation Value	779236 (r), 778363 (g)	
DyeNorm List	NA	
No of Probes in DyeNorm List	NA	

#### Spot Finding of the Four Corners of the Array



Grid Normal

Outlier Numbers with Spatial Distribution 384 rows x 164 columns





Red FeaturePopulation
 Green FeaturePopulation

Red Feature NonUniform
 Green Feature NonUniform

Metric Name	Value	Excellent	Good	Evaluate
IsGoodGrid	1.00	>1	NA	<1
AnyColorPrentFeatNonU	0.01	<1	1 to 5	>5
DerivativeLR_Spread	0.13	<0.20	0.20 to 0.30	>0.30
gRepro	0.07	0 to 0.10	0.10 to 0.20	<0 or >0.20
g_BGNoise	5.56	<10	10 to 20	>20
g_Signal2Noise	90.84	>100	50 to 100	<50
g_SignalIntensity	505.16	>400	200 to 400	<200
rRepro	0.09	0 to 0.10	0.10 to 0.20	<0 or >0.20
r_BGNolse	9.45	<10	10 to 20	>20
r_Signal2Noise	59.45	>100	50 to 100	<50
r_Signalintensity	561.64	>400	200 to 400	<200
RestrictionControl	-1.00		0.80 to 1	<0.80 or >1
LogRatioImbalance	0.00	-0.26 to 0.26	(-0.75 to -0.2	<-0.75 or >0.75

29.24

Detrend on (NegC) True Linear

#### Excellent Good Evaluate



Histogram of Signals Plot (Green)



#### **Agilent Feature Extraction**

# Microarray scan and quality control (QC Report)



#### Evaluation Metrics for CytoCGH\_QCMT\_4x\_Mar14 Excellent (10) : Good (2) : Evaluate (1)

Excellent (10) ; Good (2) ; Metric Name	Value	1) Excellent	Good	Evaluate
IsGoodGrid	1.00	>1	NA	<1
AnyColorPrcntFeatNonU	0.01	<1	1 to 5	>5
DerivativeLR_Spread	0.13	<0.20	0.20 to 0.30	>0.30
gRepro	0.07	0 to 0.10	0.10 to 0.20	<0 or >0.20
g_BGNoise	5.56	<10	10 to 20	>20
g_Signal2Noise	90.84	>100	50 to 100	<50
g_SignalIntensity	505.16	>400	200 to 400	<200
rRepro	0.09	0 to 0.10	0.10 to 0.20	<0 or >0.20
r_BGNoise	9.45	<10	10 to 20	>20
r_Signal2Noise	59.45	>100	50 to 100	<50
r_SignalIntensity	561.64	>400	200 to 400	<200
RestrictionControl	-1.00		0.80 to 1	<0.80 or >1
LogRatioImbalance	0.00	-0.26 to 0.26	(-0.75 to -0.2	<-0.75 or >0.75

• Excellent • Good • Evaluate

#### AGILENT GENOMIC WORKBENCH - COPY-NUMBER VARIATION EVALUATION (GLOBAL VIEW ON CHROMOSOMES -> CHROMOSOME 17 -> DETAIL OF 17Q11.2 MICRODELETION)



#### THE INTERPRETAION OF COPY-NUMBER VARIATIONS MUST BE PERFORMED IN THE CONTEXT OF:

- 1. Patient's phenotype
- 2. Analysis of parental genomes -> to assess CNVs origin (*de novo* or inherited CNV from parent with normal/abnormal phenotype)
- 3. Information in databases of genetic variants (UCSC, DECIPHER, DGV...) and about genes in CNVs (database OMIM)
- 4. Information in relevant scientific and clinical literature (Pubmed...)

S NCBI Resources 🛛 How To 🖓	<u>Sign in to NCBI</u>		
Publication         PubMed           US National Library of Health         Advanced	Search		
Format: Abstract - Send to - Mol Cytogenet. 2016 May 31;9:41. doi: 10.1186/s13039-016-0251-y. eCollection 2016. A novel de novo microdeletion at 17q11.2 adjacent to NF1 gene associated with developmental delay, short stature, microcephaly and dysmorphic features. Xie B <sup>1</sup> , Fan X <sup>1</sup> , Lei Y <sup>1</sup> , Chen R <sup>1</sup> , Wang J <sup>1</sup> , Fu C <sup>1</sup> , Yi S <sup>1</sup> , Luo J <sup>1</sup> , Zhang S <sup>1</sup> , Yang Q <sup>1</sup> , Chen S <sup>1</sup> , Shen Y <sup>2</sup> .	Full text links Read free full text of  BMC Full text Save items Add to Favorites		
Abstract BACKGROUND: Microdeletions at 17q11.2 often encompass NF1 gene, is the cause for NF1 microdeletion syndrome. Microdeletion at 17q11.2 without the involvement of NF1 gene is rarely reported. CASE PRESENTATION: Here we reported a patient carrying a novel de novo deletion at 17q11.2 adjacent to NF1 gene, who presented with	Similar articles  Two independent chromosomal rearrangement [Cytogenet Genome Res. 2007]		
developmental delay, short stature, postnatal microcephaly, underweight and dysmorphic features including flat facial profile, dolicocephaly, hypertelorism, short philtrum, flat nasal bridge and posteriorly rotated and low set ears. Chromosomal microarray analysis revealed a 1.69 Mb de novo deletion at 17q11.2 adjacent to NF1 gene, which involves 43 RefSeq genes. We compared this with four overlapping deletions at this interval.	A 12.4 Mb duplication of 17q11.2q12 in a patient with psychomo: [Eur J Med Genet. 201 Review Emerging genotype-phenotype relationships in patients wit [Hum Genet. 201		
CONCLUSIONS: A rare de novo microdeletion at 17q11.2 not involving NF1 gene is associated with developmental delay and dysmorphic features. Seven genes, TAOK1, PHF12, NUFIP2, SLC26A4, SEZ6, GIT1 and TRAF4 are possible candidates for the clinical features of our patient. The delineation of this rare deletion and description of associated clinical phenotypes will help to understand the genotype- phenotype correlation of genomic imbalances at this locus.	A de novo 2.9 Mb interstitial deletion at 13q12.11 in a child with c [Mol Cytogenet. 2014] Review The discovery of microdeletion		
<b>KEYWORDS:</b> 17q11.2; Chromosomal microarray; Developmental delay; Microcephaly; Microdeletion; SNP array; Short stature PMID: 27247625 PMCID: <u>PMC4886423</u> DDI: <u>10.1186/s13039-016-0251-y</u> Free PMC Article	syndromes in the post-geno [Genet Med. 2007] See reviews See all		

#### UCSC GENOME BROWSER



# **DECIPHER** <u>HTTPS://DECIPHER.SANGER.AC.UK/</u>

A STATE OF					
atient: 288	870				
Overview	Genotype	Assessments 🕡 Karyotype	Citations 0 Contacts		
Gequence Va	riants: No records found				Filter
Location	Gene / Transcript	Annotation	Inheritance / Genotype	Pathogenicity / Contribution	Links
				0	
No data available	in table				
opy-Number	r Variants: 1 to 1 of 1				Filter
Location	Class / Size G Mean Ratio		thogenicity / DS Score / ntribution Sampling F		Links
-	÷ ÷	÷ • •	÷ 0		÷
17 20050343 17 30326962	Deletion 1.27 Mb 2	7 Unknown Patl	hogenic Score:	CNV detai	IS iew -
1 7 29050343	φ φ.		-	CNV detai	IS Iew-
17 2000343 30326962	Deletion 1.27 Mb 2 -0.956619	7 Unknown Pat Heterozygous	hogenic Score:	CNV detai	IS iew -
17 2000343 30326962	Deletion 1.27 Mb 2	7 Unknown Pat Heterozygous	hogenic Score:	CNV detai	
17 2000343 30326962	Deletion 1.27 Mb 2 -0.956619	7 Unknown Pat Heterozygous 94	hogenic Score:	obabilit	IS iew →
17 3030345 Browser C ≡ Tracks	Deletion         1.27 Mb         2'           -0.956619	Unknown Heterozygous     Pat       Matching CNV Syndromes     1       2     p11.2       29.20 Mb     29.40 Mb	hogenic Score: Sampling pro	оbabilit q22 q23 2 q24.2 q2 30.00 Mb 30.20 Mb	43 q25.1 q25.3 <b>&lt; &gt;</b>
17 2000343 30030562 Browser G	Deletion         1.27 Mb         2'           -0.956619	Unknown Heterozygous     Pat       Matching CNV Syndromes     1       2     p11.2       29.20 Mb     29.40 Mb	hogenic         Score: Sampling pro           012         q21.2         q21.31           29.00 Mb         29.80 Mb           RAB11FIP4 >         CMIG	орафій q22 q23.2 q24.2 q2 30.00 Mb 30.20 Mb	43 q25.1 q25.3
17 3030345 Browser C ≡ Tracks	Deletion         1.27 Mb         2'           -0.956619	7     Unknown Heterozygous     Pat       Matching CNV Syndromes     1       2     p112     1       2     p14     1	ogenic         Score: Sampling pro           012         021.2         021.31           29.00 Mb         29.80 Mb           29.00 Mb         29.80 Mb           RAB11FIP4 >         RAB11FIP4 >	орафій 922 923 2 9242 92 30.00 Mb 30.20 Mb Соряз 1	43 q25.1 q25.3 <b>&lt; &gt;</b>
17 20000345 Browser G ≡ Tracks	Deletion         1.27 Mb         2'           -0.956619	Vinknown Heterozygous     Pate       Matching CNV Syndromes     1       2     911.2       2     911.2       2     912       2     913       2     913       2     913       2     913       2     913       2     913       2     913       2     914       2     913       2     914	hogenic Score: Sampling pro	022 023 2 0242 02 30.00 Mb 50 20 Mb C COPPS UTPO SU212 >	43 q25.1 q25.3
17 20000345 Browser C ≡ Tracks	Deletion         1.27 Mb         2'           -0.956619	Vinknown Heterozygous     Pate       Matching CNV Syndromes     1       2     911.2       2     911.2       2     912       2     913       2     913       2     913       2     913       2     913       2     913       2     913       2     914       2     913       2     914	hogenic Score: Sampling pro	орафій 922 923 2 9242 92 30.00 Mb 30.20 Mb Соряз 1	43 q25.1 q25.3 < > 50.40 Mb 502 Q Q RRC37B > RH0T1 > ≪ Q Q ↔ [] n the CNV
17 20000345 Browser G ≡ Tracks	Deletion         1.27 Mb         2           -0.956619         2           Denes         27           Matching Patients         35           Chr 17         (P13.3)         (P13.2)           28.80 Mb         29.00 Mb         CRLF3           20.9581 B         CRLF3         CRLF3           pLl ranges:         0.0         0.1         0.2	Vinknown Heterozygous     Pate       Matching CNV Syndromes     1       29 20 Mb     29 40 Mb       THEFM     NF1>       ACXX2>     NF1>       0.3     0.4     0.5     0.5     0.7	ogenic         Score: Sampling pro           012         q21.2         q21.31           29.00 Mb         29.80 Mb           COMO         RAB11FIP4 >           COMO         EVI2A           0.8         0.9	022 023 2 0242 02 30.00 Mb 50 20 Mb C COPPS UTPO SU212 >	43 q25.1 q25.3
17 2000045 Browser G ≡ Tracks Genes Genes Legend	Deletion         1.27 Mb         2           -0.956619         2           Denes         27           Matching Patients         35           Chr 17         (P13.3)         (P13.2)           28.80 Mb         29.00 Mb         CRLF3           20.9581 B         CRLF3         CRLF3           pLl ranges:         0.0         0.1         0.2	7     Unknown Heterozygous     Pate       Matching CNV Syndromes     1       29 20 Mb     29 40 Mb       29 20 Mb     29 40 Mb       THEFM     NF1>       ADXX2>     NF1>       0.3     0.4     0.5     0.6     0.7       Intelerance to LoF mutation     -	ogenic         Score: Sampling pro           012         q21.2         q21.31           29.00 Mb         29.80 Mb           COMO         RAB11FIP4 >           COMO         EVI2A           0.8         0.9	022 023 2 0242 02 30.00 Mb 50 20 Mb C COPPS UTPO SU212 >	43 q25.1 q25.3 < > 30.40 Mb 500t Q Q RRC57B > RH0T1 > < 0 Q Q → [] n the CNV t ±
17 2000045 Browser G ≡ Tracks Genes Genes Legend	Deletion         1.27 Mb         2           -0.956619         2           Denes         27           Matching Patients         35           Chr 17         (P13.3)         (P13.2)           28.80 Mb         29.00 Mb         CRLF3           20.9581 B         CRLF3         CRLF3           pLl ranges:         0.0         0.1         0.2	7     Unknown Heterozygous     Pate       Matching CNV Syndromes     1       29 20 Mb     29 40 Mb       29 20 Mb     29 40 Mb       THEFM     NF1>       ADXX2>     NF1>       0.3     0.4     0.5     0.6     0.7       Intelerance to LoF mutation     -	ogenic         Score: Sampling pro           012         q21.2         q21.31           29.00 Mb         29.80 Mb           COMO         RAB11FIP4 >           COMO         EVI2A           0.8         0.9	022 023 2 0242 02 30.00 Mb 50 20 Mb C COPPS UTPO SU212 >	43 q25.1 q253 50.40 Mb 502 Q Q RRC37B > RHOT1 > ≪ ♥ Q Q H E N the CNV ↓ ± ≪ ♥ ♡

### OMIM (WWW.OMIM.ORG)

*613113 Table of Contents	* 61311	3				▼ External Links		
Title						▶ Genome		
Cene-Phenotype Relationships	NEUR	OFIBROMIN 1; NF1				► DNA		
Text Description	Alternative t	itles; symbols				▶ Protein		
Cloning and Expression	NEUROI	FIBROMIN				► Gene Info		
Gene Structure	BONG A.	10				Clinical Resources		
Mapping	HGNCAP	proved Gene Symbol: NF1	<b>v</b> Variation					
Gene Function Molecular Genetics	Cytogene: NCBI)	tic location: 17q11.2 Genomic coo	1000 Genome ClinVar gnomAD GWAS Catalog External dat					
Animal Model History	Gene-Ph	enotype Relationships		External databa				
Allelic Variants Table View	Location	Phenotype	Phenotype MIM number	Inheritance	Phenotype mapping key	GWAS Central HGMD HGVS	(click to oper	
References	17 911 2	Leukemia, juvenile myelomono cytic	607785	SMu, AD	3.	NHLBI EVS Pharm GKB		
Contributors		Neurofibromatosis, familial spinal	162210	AD	3.	Pharmukb		
Creation Date		Neurofibromatosis, type 1	162200	AD	3.	Animal Models		
Edit History		Neurofibromatosis-Noonan syndrome Watson syndrome	601321 193520	AD AD	3.	Cellular Pathways		
OUT THE G	ENE	ne Graphics 🔹 🔍			<u> </u>	Associated r	oathologies	

The NF1 gene encodes neurofibromin, a cytoplasmic protein that is predominantly expressed in neurons, Schwann cells, oligodendrocytes, and leukocytes. It is a multidomain molecule with the capacity to regulate several intracellular processes, including the RAS (see 190020)-cyclic AMP pathway, the ERK (600997)/MAP (see 600178) kinase cascade, adenylyl cyclase, and cytoskeletal assembly (summary by Trovo-Marqui and Tajara, 2006).

#### Cloning and Expression

Buchberg et al. (1990) sequenced a portion of the murine NF1 gene and showed that the predicted amino acid sequence is nearly the same as the corresponding region of the human NF1 gene product. Computer searches identified homology between the mouse NF1 gene and the Ira1 and Ira2 genes identified in Saccharomyces cerevisiae, which negatively regulate the RAS-cyclic AMP pathway. RAS proteins are involved in the control of proliferation and differentiation in mammalian cells. Their activity is modulated by their ability to bind and hydrolyze guanine nucleotides. GTP-binding activates RAS, whereas GTP hydrolysis inactivates RAS. Mutant forms of RAS found in human tumors have greatly decreased GTPase activity, resulting in accumulation of RAS in the GTP-bound active form.

#### Details about the gene

# ADVANTAGES AND DISADVANTAGES OF ARRAY-CGH

#### • <u>advantages</u>

- detects and quantifies DNA copy number gains and losses throughout an entire genome in a single analysis
- resolution depends on microarray platform of the choice (from ~50 kb)
- ability to detect mosaicism < 30%</li>
- precise aberration location (based on aberrant clone positions)

#### <u>disadvantages</u>

- unable to detect balanced rearrangements (translocation, inversion)
- unable to detect ploidy changes
- very expensive method
- highly qualified and experienced laboratory stuff

#### **MLPA** MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION

- sensitive method able to detect differences up to nucleotide level
- detects changes of copy number in 45 sequences in one reaction
- simple all the reaction takes place in one test tube
- relatively cheap method



## MLPA PRINCIPLE (IN BRIEF)







### ADVANTAGES AND DISADVANTAGES OF MLPA

- <u>advantages</u>
  - sensitive
  - specific
  - multiplex
  - simple
  - cheap
- <u>disadvantages</u>
  - highly sensitive to contamination
  - time difficulty
  - the aberrations have to occur in 50% of cells (mosaicism)
  - mutations or polymorphisms can lead to false results

# **5. CASE INTERPRETATION**

### CASE INTERPRETATION 1

- girl, born in 2002
- dg: stigmatization mongoloid eye position, hyperplastic gingival mucose membrane, atypical chest and tummy
- mother 46,XX, inv(9), <u>father 46,XY,add(1)[87]/46,XY[13]</u>



CIR.	2	10 10 3	Sec.50				e s
STREET,	Electro -	Real B	45-45 S	00 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	(日本) (日本) (日本) (日本) (日本) (日本) (日本) (日本)	12 12	
13	14 14	15			16	17	<b>B B 1</b> 8
13	14	15		Ē	16	17	18

46,XX,add(1)

### CGH: rev ish enh (11p15-pter) – unbalanced translocation



# CASE INTERPRETATION 2

- boy, born in 2004
- heart defect, facial dysmorphology



45,XY,-22,der(14)

46,XX,der(14)t(14;22)(q32.3;q11.2)



45,XY,der(14)t(14;22)(q32.3;q11.2) DiGeorge sy

### 46,XX,der(14)t(14;22)(q32.3;q11.2)

# CASE INTERPRETATION 3

- boy, born in 2018
- <u>severe lissencephaly</u>, global developmental delay



### GENOTYPE-PHENOTYPE CORRELATION

### (OMIM DATABASE)



# GENOTYPE-PHENOTYPE CORRELATION (OMIM DATABASE)

#607432 Table of Contents	ICD+							▼ External Links
Title	# 607432							Protein
Phenotype-Gene Relationships	LISSE	NCEPHALY 1; <mark>LIS</mark>	51					<ul> <li>Clinical Resources</li> </ul>
Clinical Synopsis Phenotypic Series	Alternative	titles; symbols						Clinical Trials EuroGentest Gene Reviews
Text Description		LISSENCEPHALY SEQUENCE, ISOLATED; ILS LISSENCEPHALY, CLASSIC						Genetic Alliance Genetics Home Reference
Clinical Features Molecular Genetics	Other entities represented in this entry:							GTR GARD Corphanet
Genotype/Phenotype Correlations Animal Model References	INCLU	ORTICAL LAMIN UDED rtical band heter(					CLH,	Animal Models
Contributors Creation Date	Phenoty	pe-Gene Relationships						
Edit History	Location	Phenotype	Phenotype MIM number	Inheritance	Phenotype mapping key	Gene/Locus	Gene/Locus MIM number	
	17p13.3	Subcortical laminar heterotopia	607432	AD	3	PAFAH1B1	601545	
	17p13.3	Lissencephaly 1	607432	AD	3	PAFAH1B1	601545	

▼ TEXT

A number sign (#) is used with this entry because lissencenhaly-1 (LISI) and subcortical hand

Phenotypic Series

PheneGene Graphics -

Ð

#### GENOTYPE-PHENOTYPE CORRELATION (PUBMED)

#### ORIGINAL CONTRIBUTION

#### LIS1-Related Isolated Lissencephaly

#### Spectrum of Mutations and Relationships With Malformation Severity

Yoann Saillour, PhD; Nathalie Carion, MS; Chloe Quelin, MD; Pierre-Louis Leger, MD; Nathalie Boddaert, MD, PhD; Caroline Elie, MD; Annick Toutain, MD, PhD; Sandra Mercier, MD; Marie Anne Barthez, MD; Mathieu Milh, MD, PhD; Sylvie Joriot, MD; Vincent des Portes, MD, PhD; Nicole Philip, MD, PhD; Dominique Broglin, MD; Agathe Roubertie, MD, PhD; Gaelle Pitelet, MD; Marie Laure Moutard, MD; Jean Marc Pinard, MD; Claude Cances, MD; Anna Kaminska, MD; Jamel Chelly, MD, PhD; Chérif Beldjord, MD, PhD; Nadia Bahi-Buisson, MD, PhD

**Objective:** With the largest data set of patients with *LIS1*related lissencephaly, the major cause of posteriorly predominant lissencephaly related to either *LIS1* mutation or intragenic deletion, described so far, we aimed to refine the spectrum of neurological and radiological features and to assess relationships with the genotype.

Design: Retrospective study.

**Subjects:** A total of 63 patients with posteriorly predominant lissencephaly.

**Interventions:** Of the 63 patients, 40 wer either *LIS1* point mutations (77.5%) or sm letions (20%), and 1 carried a somatic n tion. On the basis of the severity of neur ment, epilepsy, and radiological findings, cl the location and type of mutation were ex

**Results:** Most patients with *LIS1* mut strated posterior agyria (grade 3a, 55.3%)

pus callosum (50%) and prominent perivascular spaces (67.4%). By contrast, patients without *LIS1* mutations tended to have less severe lissencephaly (grade 4a, 41.6%) and no additional brain abnormalities. The degree of neuromotor impairment was in accordance with the severity of lissencephaly, with a high incidence of tetraplegia (61.1%). Conversely, the severity of epilepsy was not determined with the same reliability because 82.9% had early onset of seizures and 48.7% had seizures more often than daily. In addition, neither the mutation type nor the location of the mutation were found to predict the sever

S NCBI Resources V How To V	<u>Sign in to NCBI</u>
Publicad.gov         PubMed         I           US Netional Library of Medicine National Institutes of Health         Advanced	Search
Format Abstract - Send to -	
<u>Pediatr Neurol</u> 2007 Apr;86(4):258-60.	Full text links           ELSEVIER           FULL-TEXT ARTICLE
Partial deletion of LIS1: a pitfall in molecular diagnosis of Miller-Dieker syndrome.	
Izumi K <sup>1</sup> , Kuratsuji G, Ikeda K, Takahashi T, Kosaki K.	Save items
Author information	Add to Favorites
Abstract	
Miller-Dieker syndrome represents a microdeletion syndrome spanning the LIS1 locus at 17p13.3, the deletion of which leads to lissencephaly. A fluorescence in situ hybridization study using an LIS1 probe is considered the standard laboratory diagnostic method for	Similar articles
Miller-Dieker syndrome. This report documents a Miller-Dieker syndrome patient who tested normal when a commercially available LIS1 fluorescence in situ hybridization study probe was used but was later demonstrated to have a partial deletion of the LIS1 locus. The present	[A case of Miller-Dieker syndrome associated with satellite on chromosome [Rinsho Byori. 2001]
case exemplifies a major shortcoming of commercially available fluorescence in situ hybridization studies for the diagnosis of microdeletion syndromes such as Miller-Dieker syndrome: that is, relatively small deletion can potentially remain undetected.	Genomic copy number variations at 17p13.3 and epileptogenesis. [Epilepsy Res. 2010]
PMID: 17437911 DOI: 10.1016/j.pediatmeurol.2006.11.015	A revision of the lissencephaly and Miller-Dieker
[Indexed for MEDLINE]	syndrome critical regions [Hum Mol Genet. 1997]
	<b>Review</b> Lissencephaly and LIS1: insights into the molecular mechanisms of r [Clin Genet. 2007]
	Review Lissencephaly and the molecular basis

Publication types, MeSH terms, Substances

### THANK YOU FOR YOUR ATTENTION